Taysha Gene Therapies, Inc. TSHA
Set alert
4.00 USD -0.13 -3.15%
At close · Nov 2
4.00 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
3.95 Day range 4.20
3.46 52-week range 7.30
- YTD
- -27.27%
- 1 year
- -19.35%
- Open
- 4.30
- Prev close
- 4.13
- Mkt cap
- 1.30B
- Vol
- 2.01M
- Avg vol
- 3.54M
- EPS
- -0.40
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.95
- High
- 4.20
- Forward P/E
- -8.65
- Beta
- 1.31
- Short ratio
- 10.79
- Inst. own
- 94.28%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 4.82
- 200-d avg
- 5.32
- 1y target
- 13.00
2Y chart
Events in this range
- Aug 12, 2025Earnings: -0.09; estimate -0.07; surprise -28.57%
- Nov 4, 2025Earnings: -0.09; estimate -0.09; surprise 0%
- Mar 19, 2026Earnings: -0.08; estimate -0.11; surprise 27.27%
- May 6, 2026Earnings: -0.12; estimate -0.1; surprise -20%
- Jun 23, 2026Rating: BMO Capital · Outperform → Outperform
- Jun 30, 2026Rating: Baird · Outperform → Outperform
- Jun 30, 2026Rating: Needham · Buy → Buy
- Jul 2, 2026Rating: Citizens · Market Outperform → Market Outperform
- Jul 21, 2026Rating: Goldman Sachs · Buy → Buy
- Aug 11, 2026Earnings: -0.13; estimate -0.11327; surprise -14.77%
- Sep 17, 2026Rating: Wolfe Research · — → Outperform
Signals (84)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| RSI: Oversold | Oct 12, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 6, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 2, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 29, 2026 | 1 month ago |
| RSI: Oversold | Sep 25, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Aug 26, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 21, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 3 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Jul 16, 2026 | 3 months ago |
| SMA: Bullish | Jul 15, 2026 | 3 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 8, 2026 | 3 months ago |
| SMA: Bullish | Jun 17, 2026 | 4 months ago |
Newest 20 of 84.
Key statistics
- Market cap
- 1.30B
- Enterprise value
- 947.00M
- Trailing P/E
- 0.00
- Forward P/E
- -8.65
- PEG ratio
- 0.00
- Price / sales
- 237.62
- Price / book
- 3.36
- EPS (TTM)
- -0.41
- Beta
- 1.31
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 5.49M
- Revenue growth
- 0.00%
- Free cash flow
- -80.97M
- Total cash
- 455.41M
- Total debt
- 56.71M
- Return on equity
- -47.05%
- Shares outstanding
- 325.83M
- Short % of float
- 15.98%
- 50-day average
- 4.82
- 200-day average
- 5.32
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 13.00 +225.0% upside
Now 4.00
- Target (low)
- 9.00
- Target (mean)
- 13.00
- Target (high)
- 19.00
Ratings (0m) 13 13 buy · 0 hold · 0 sell
- Strong buy3
- Buy10
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate -0.125.
Financials — quick view
TSHA Revenue — quarterly 0
TSHA Net income — quarterly -46.64M
TSHA EPS — quarterly -0.13
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -0.12857 | — | — | — |
| Aug 11, 2026 | Jun 30, 2026 | -0.11327 | -0.13 | -0.02 | -14.77% |
| May 6, 2026 | Mar 31, 2026 | -0.10 | -0.12 | -0.02 | -20.00% |
| Mar 19, 2026 | Dec 31, 2025 | -0.11 | -0.08 | +0.03 | +27.27% |
| Nov 4, 2025 | Sep 30, 2025 | -0.09 | -0.09 | 0.00 | 0.00% |
| Aug 12, 2025 | Jun 30, 2025 | -0.07 | -0.09 | -0.02 | -28.57% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 17, 2026 | Wolfe Research | init | — | Outperform |
| Jul 21, 2026 | Goldman Sachs | main | Buy | Buy |
| Jul 2, 2026 | Citizens | reit | Market Outperform | Market Outperform |
| Jun 30, 2026 | Needham | main | Buy | Buy |
| Jun 30, 2026 | Baird | main | Outperform | Outperform |
| Jun 23, 2026 | BMO Capital | main | Outperform | Outperform |
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tayshagtx.com
News
- Taysha Gene Therapies (NASDAQ:TSHA) Hits New 52-Week Low – Time to Sell?
- Taysha Gene Therapies (NASDAQ:TSHA) versus MediWound (NASDAQ:MDWD) Head to Head Analysis
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Taysha Gene Therapies Presents Multiple Encore Presentations For Its TSHA-102 Program At 55th Child Neurology Society Annual Meeting
- Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
- Wolfe Research Initiates Coverage On Taysha Gene Therapies with Outperform Rating
- Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval
- These 3 Risky Stocks Could Be Sitting on 100% Upside
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Bank of America Corp DE Has $7.50 Million Stake in Taysha Gene Therapies, Inc. $TSHA
Your note
Sign in to keep a note on TSHA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALAM KAMRAN | Chief Financial Officer | Sale | Feb 3, 2026 | 1,442,130 |
| DONENBERG PHILLIP BRIAN | Director | Stock Award(Grant) | May 31, 2026 | 241,289 |
| LONG ALISON S | Director | Stock Award(Grant) | May 31, 2026 | 127,178 |
| MANNING PAUL B. | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 29, 2025 | 0 |
| NAGENDRAN SUKUMAR | Officer and Director | Sale | Jul 9, 2026 | 936,410 |
| NOLAN SEAN PATRICK | Chief Executive Officer | Sale | Jan 25, 2026 | 4,443,800 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 7.33% | 23,888,888 | 95.56M | Jun 29, 2026 |
| RA Capital Management, L.P. | 7.23% | 23,555,648 | 94.22M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 6.97% | 22,713,118 | 90.85M | Jun 29, 2026 |
| Blackrock Inc. | 6.35% | 20,691,927 | 82.77M | Jun 29, 2026 |
| Vestal Point Capital, LP | 5.96% | 19,415,000 | 77.66M | Jun 29, 2026 |
| Morgan Stanley | 5.06% | 16,487,479 | 65.95M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.80% | 9,138,043 | 36.55M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.12% | 6,895,325 | 27.58M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.58% | 5,138,803 | 20.56M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.28% | 4,170,948 | 16.68M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.93% | 3,044,554 | 12.18M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.80% | 2,622,724 | 10.49M | Jul 30, 2026 |